Related Experiment Video
Updated: Apr 25, 2026
09:21
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
119
Towards developing biomarkers for glioblastoma multiforme: a proteomics view.
Savita Jayaram1, Manoj Kumar Gupta, Ravindra Varma Polisetty
1Institute of Bioinformatics, International Tech Park, Bangalore, 560066, India.
Expert Review of Proteomics
|August 14, 2014
Summary
Glioblastoma multiforme (GBM) research needs new biomarkers. Integrating multi-omics data and analyzing protein secretion offers novel insights for developing tissue and blood-based assays for this aggressive brain tumor.
Area of Science:
- Neuro-oncology
- Genomics
- Proteomics
Background:
- Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with significant heterogeneity.
- Current diagnostic and therapeutic approaches require improved molecular markers for accurate typing and monitoring.
- Tumor heterogeneity necessitates novel strategies for identifying reliable biomarkers.
Purpose of the Study:
- To review potential biomarker candidates for Glioblastoma multiforme.
- To explore multi-omics data integration for identifying novel GBM molecular panels.
- To discuss pipelines for discovering tissue and circulatory biomarkers for GBM.
Main Methods:
- Literature review of reported GBM biomarker candidates.
- Bioinformatic analysis of protein secretory potential.
- Exploration of multi-omics data integration strategies.
- Analysis of tumor cell secretome and exosomes.
Main Results:
- Potential biomarker candidates for GBM have been reported in existing literature.
- Multi-omics data integration offers insights into GBM pathogenesis.
- Analysis of protein secretion pathways can identify potential circulatory biomarkers.
- Novel high-confidence molecular panels can be identified through integrated approaches.
Conclusions:
- Developing new tissue-based and blood-based assays is crucial for GBM management.
- Multi-omics integration and secretome analysis are promising avenues for biomarker discovery.
- Identification of robust biomarker panels will enhance clinical applications in GBM.
